Tevard Biosciences

Executive Summary

Tevard Biosciences is a private, preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies for patients with rare genetic diseases, with an initial emphasis on Dravet syndrome. Founded in 2017 by renowned MIT molecular cell biologist Professor Harvey Lodish, alongside Daniel Fischer and Warren Lammert—both parents of children with Dravet syndrome—the company leverages deep expertise in genetic medicine to create lifelong cures. Tevard's proprietary platform aims to address the underlying genetic causes of severe epilepsy and other monogenic disorders by delivering durable, one-time treatments. The company operates at the intersection of cutting-edge gene therapy and patient-centric drug development, guided by a leadership team that combines academic excellence with firsthand experience of the patient journey. As a preclinical entity, Tevard has yet to disclose detailed pipeline progress or funding history, but its focus on Dravet syndrome—a serious, treatment-resistant epilepsy with high unmet need—positions it for potential rapid advancement. The company's emphasis on novel gene therapy approaches suggests it may pursue regulatory milestones such as Investigational New Drug (IND) applications or Orphan Drug Designations in the near term. Key upcoming catalysts could include the initiation of first-in-human clinical trials, strategic partnerships or licensing deals, and additional preclinical data readouts supporting lead programs. Given the competitive landscape in genetic epilepsies, successful execution of these milestones will be critical for Tevard to differentiate itself and attract further investment.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Dravet Syndrome Gene Therapy55% success
• H2 2026Partnership or Licensing Deal for Proprietary Platform40% success
• Q4 2026Preclinical Proof-of-Concept Data in Dravet Syndrome Models70% success